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ABSTRACT
Background: The use of targeted therapies has
recently increased. Pharmacogenetic tests are a
useful tool to guide patient treatment and to
test a response before administering medicines.
Pharmacogenetic tests can predict potential
drug resistance and may be used for
determining genotype-based drug dosage.
However, their cost-effectiveness as a
diagnostic tool is often debatable. In Germany,
47 active ingredients are currently approved. A
prior predictive test is required for 39 of these
and is recommended for eight. The objective of
this study was to review the cost-effectiveness
(CE) of pharmacogenetic test-guided drug
therapy and compare the application of drugs
with and without prior genetic testing.
Methods: A systematic literature review was
conducted to identify the CE and cost-utility
of genetic tests. Studies from January 2000 until
November 2015 were searched in 16 databases
including Medline, Embase, and Cochrane. A
quality assessment of the full-text publications
was performed using the validated Quality of
Health Economic Studies (QHES) instrument.
Results: In the majority of the included studies,
the pharmacogenetic test-guided therapy
represents a cost-effective/cost-saving
treatment option. Only seven studies lacked a
clear statement of CE or cost-savings, because of
uncertainty, restriction to specific patient
populations, or assumptions for comparative
therapy. Moreover, the high quality of the
available evidence was evaluated.
Conclusion: Pharmacogenetic testing
constitutes an opportunity to improve the CE
of pharmacotherapy. The CE of targeted
therapies depends on various factors including
costs, prevalence of biomarkers, and test
sensitivity and specificity. To guarantee the CE
comparability of stratified drug therapies,
national and international standards for
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evaluation studies should be
defined.
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INTRODUCTION
Adverse drug reactions (ADRs) are often
responsible of morbidity and mortality [1]. In
the USA, it has been estimated that 106,000
deaths per year are caused by ADRs [2]. In
Germany, the incidence of ADR-induced
hospitalizations amounts to approximately
3.25% of overall hospitalizations, and the
overall ADR treatment costs sum to €434
million per year [3]. The field of
pharmacogenomics or pharmacogenetics (PG),
these terms are sometimes used interchangeably
[4, 5], may be a solution to reduce ADRs [6]. PG
constitutes a core area of personalized
medicine. The growing knowledge of genetics/
genomics, and particularly the increasing
understanding of the genotype–phenotype
interaction, forms the basis for this
personalized approach. The progress in genetic
technology, characterized by faster and cheaper
analytical tools, is an essential driver for
personalized interventions.
Genetic analyses are the central tools in the
new area of personalized medicine (often also
termed stratified medicine) [7, 8]. Stratified
medicine aims at classifying patients into
subgroups according to genetically determined
features [9]. For example, patients may be
divided into groups based on the known
influence of genetic parameters on drug
dosage and side effects [10]. Therefore, PG uses
information about a person’s genetic makeup to
choose the best drug as well as the medication
dosage for a particular patient [11]. The concept
of stratified medicine also includes screening,
preventive, or therapeutic measures for a
specific subgroup of a patient population [12].
Pharmacogenetic tests (PTs) can be used to
characterize individual patient features at the
molecular, genetic, and cellular levels [13, 14].
PT primarily focuses on identifying specific
biomarkers or genetic mutations. Generally,
biomarkers can provide information for
diagnostic, prognostic, and predictive purposes.
In a diagnostic context (especially in an
oncologic setting), biomarkers are used to
identify a disease or the stage of the disease
[15]. The assessment of a patient’s overall
outcome (e.g., the probability of cancer
recurrence after standard treatments) can be
provided by prognostic biomarkers [16].
Furthermore, in a predictive context,
biomarkers are used as an efficacy test before
drug administration. This test serves the purpose
of assessing the likelihood of a positive response
after a potential treatment. In this context,
predictive biomarkers can help to optimize
drug selection, dose, and treatment duration as
well as prevent ADRs [17].
The presence of genetic mutations or deletions
can also be used for predictive purposes. Several
studies have demonstrated that previously
identified genetic mutations, such as those on
the epidermal growth factor receptor (EGFR),
Kirsten RAS (KRAS), and the breast cancer
susceptibility gene I and II (BRCA I, BRCA II),
predict resistance to treatment [18, 19]. For
example, an identified EGFR gene mutation or
an increased EGFR gene copy number is
associated with a positive response to epidermal
growth factor receptor tyrosine kinase inhibitors
(EGFR-TKI) in non-small cell lung cancer
(NSCLC) [20]. On the other hand, a KRAS
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mutation is an important predictor for resistance
to an EGFR-TKI therapy [21]. Moreover, gene
mutations can also provide information for
optimal drug dosage. For instance, the dosage of
azathioprine (AZA) is based on the
thiopurine-methyltransferase (TMPT) genotype
or activity. Patients with no TMPT activity
(TMPT deficient) receive no or a reduced dose of
AZA, whereas the dosage of AZA administered in
patients with an active TMPT differs [12, 22].
The outdated concept of ‘‘one size fits all’’
should be replaced by stratification and move
towards a patient-oriented drug treatment [23].
However, this concept is equally connected to
hopes and concerns. Potential advantages of
target therapies include increasing clinical
effectiveness, e.g., by improving survival [24],
and improving patient safety [25]. On the other
hand, there are concerns regarding the
increased costs of diagnostic tests [26].
However, in recent years, an increasing
number of pharmacogenomics applications have
been observed [27]. Currently, 47 drugs for
pharmacogenetic therapy are approved in
Germany. A genetic diagnostic test prior to drug
administration is required for 39 of these drugs
and recommended for eight [28]. An overview of
pharmacogenetic therapies is provided in
supplementary file 1. The sustainability of the
current trend for stratified pharmacotherapies
depends on the cost-effectiveness (CE) of the
treatment. The incremental cost-effectiveness
ratio (ICER) is a tool to assess the CE of new
interventions and is defined as the ratio of the
additional costs (e.g., of a new stratified therapy
vs. the standard therapy) divided by the
additional benefits of the new stratified therapy
vs. the standard therapy. The ICER also indicates
the cost per additional benefit [e.g., life-years
gained (LYG) or quality-adjusted life years gained
(QALY)]. Such economic analyses are necessary
for identifying therapies with the greatest health
benefits at acceptable costs, as well as for the
development of guidelines for an optimal and
efficient treatment. The use of PTs depends on
their impact on the CE of targeted therapies. As a
result of the limited resources in the healthcare
system and the sometimes substantial costs for
active ingredients, it is important to evaluate the
CEs of PT-guided targeted therapies.
For this purpose, we conducted a systematic
literature review to analyze the CE of stratified
pharmaceutical therapies. The review has two
objectives:
1. Analyze and assess the CE of PT-guided
treatments in published health-economic
evaluation studies.
2. Highlight the differences and
methodological characteristics of the
included studies, which may influence the
CE of stratified therapies.
METHODS
First, PICO elements (population–intervention
–comparator–outcome) were defined in order to
focus the scientific issue and facilitate the
literature search (Table 1).
In November 2015, a systematic literature
search was conducted using the meta-database
of the German Institute for Medical
Documentation and Information (DIMDI) in
the following databases: ABDA, AMIS, BIOSIS
Previews, Cochrane Central Register of
Controlled trials, Cochrane Databases of
Systematic Reviews, DAHTA-Datenbank,
Database of Abstracts of Reviews of Effects,
EMBASE, EMBASE Alert, ETHMED, GLOBAL
Health, gms, Health Technology Assessment
Database, Medline, NHS, and SciSearch. The
search strategy combines economic
individualized medicine-related terms with the
names of active ingredients. At the time of this
research, there were 42 active ingredients
Adv Ther (2016) 33:1461–1480 1463
approved for personalized medicine in the
German market [28]. The following search
strategy, using combined search terms (English
and German), was applied: (1) [Abacavir OR
Afatinib OR Anastrozole OR Arsentrioxid OR
Ataluren OR Azathioprine OR Bosutinib
OR Brentuximab vedotin OR Carbamazepine
OR Cetuximab OR Crizotinib OR Ceritinib OR
Dabrafenib OR Dasatinib OR Eliglustat OR
Erlotinib OR Everolimus OR Exemestane
OR Fulvestrant OR Gefitinib OR Ibrutinib OR
Imatinib OR Ivacaftor OR Lapatinib OR
Letrozole OR Lomitapide OR Maraviroc
OR Mercaptopurine OR Natalizumab OR
Nilotinib OR Olaparib OR Oxcarbazepine OR
Panitumumab OR Pertuzumab OR Ponatinib
OR Tamoxifen OR Toremifene OR Trametinib
OR Trastuzumab OR Trastuzumab emtansine
OR Vandetanib OR Vemurafenib] AND (2)
[Biomarker OR individuali* OR personali* OR
stratif* OR Subgruppe* OR subgroup* OR
pharmakogen* OR pharmacogen* OR Test*
OR profiling] AND (3) [Nutzen OR benefit OR
Nutzwert OR utility OR Effektivita¨t OR
effectiveness OR effizien* OR efficien*] AND
(4) [Kosten* OR cost* OR technology
assessment]. The operator ‘‘AND’’ combined
the search terms while an asterisk was used as
a truncation for a greater search coverage.
Additionally, a search was conducted by hand.
Assessment of titles and abstracts was
performed independently by two researchers.
Only original studies published in full text were
included. Full papers were assessed by two
researchers, and disagreements were resolved
through discussion. Figure 1 summarizes the
search process.
Fig. 1 Flow diagram of articles identiﬁed and evaluated on
the basis of inclusion criteria
Table 1 Review objective and PICO elements
Review objective To review the economic impact of PT-guided therapies; highlight the differences and
methodological characteristics of the included studies
Populations Studies of participants who received a pharmacogenetic therapy; studies were not restricted
to speciﬁc indications
Interventions/comparison Studies that compare the application of targeted agents with prior genetic testing to those
without prior genetic testing. The review is not limited to speciﬁc comparators
Outcomes ICER (e.g., cost per QALY, cost per LYG, cost per avoided HSR/ADR)
PICO population–intervention–comparator–outcome, QALY quality-adjusted life year, LYG life-years gained, HSR
hypersensitivity reaction, ADR adverse drug reaction
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To ensure comparability, the results were
converted to US dollars at the exchange rate of
the year of publication [29, 30].
The published 100-point Quality of Health
Economic Studies (QHES) instrument was used
to evaluate the quality of the included studies
(Table 2) [31]. The QHES evaluation was also
conducted by two independent researches, and
the disagreements were resolved through
discussion.
Table 2 The Quality of Health Economic Studies (QHES) instrument
Questions Points Yes/no
1. Was the study objective presented in a clear, speciﬁc, and measurable manner? 7
2. Were the perspective of the analysis (societal, third-party payer, etc.)
and reasons for its selection stated?
4
3. Were variable estimates used in the analysis from the best available source
(i.e., randomized control trial—best, expert opinion—worst)?
8
4. If estimates came from a subgroup analysis, were the groups prespeciﬁed
at the beginning of the study?
1
5. Was uncertainty handled by (1) statistical analysis to address random events,
(2) sensitivity analysis to cover a range of assumptions?
9
6. Was incremental analysis performed between alternatives for resources and costs? 6
7. Was the methodology for data abstraction (including the value of health states
and other beneﬁts) stated?
5
8. Did the analytic horizon allow time for all relevant and important outcomes?
Were beneﬁts and costs that went beyond 1 year discounted (3–5%) and
justiﬁcation given for the discount rate?
7
9. Was the measurement of costs appropriate and the methodology for the estimation
of quantities and unit costs clearly described?
8
10. Were the primary outcome measure(s) for the economic evaluation clearly stated
and were the major short-term, long-term, and negative outcomes included?
6
11. Were the health outcomes measures/scales valid and reliable? If previously tested
valid and reliable measures were not available, was justiﬁcation given for the
measures/scales used?
7
12. Were the economic model (including structure), study methods and analysis, and the
components of the numerator and denominator displayed in a clear, transparent manner?
8
13. Were the choice of economic model, main assumptions, and limitations of the study
stated and justiﬁed?
7
14. Did the author(s) explicitly discuss direction and magnitude of potential biases? 6
15. Were the conclusions/recommendations of the study justiﬁed and based on the
study results?
8
16. Was there a statement disclosing the source of funding for the study? 3
Total points
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This evaluation consists of 16 items, each
providing a score between one and nine. The
overall evaluation, after summing the scores of
each item, identified the quality of an article,
which was categorized into four groups (Table 3).
The evaluation of the article quality was also
conducted by two independent experts.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
The database search identified 1535 records.
After removing 175 duplicates, the title and
abstract of the remaining 1360 records were
screened. Subsequently, 1238 records were
excluded as they did not cover the objective
of the study. The remaining 122 records were
assessed for eligibility, and inclusion criteria
were fulfilled by 27 studies, which were
included in the final assessment (Fig. 1).
All studies are characterized by a variety of
elements, such as country, perspective,
treatment line, active ingredient, treatment
strategy, biomarkers, consideration of test costs,
consideration of sensitivity, and specificity of the
test and funding source. A detailed overview is
provided in supplementary material 2.
Quality Assessment (QHES)
The results of the quality assessment using the
QHES instrument are presented in Table 4. An
average value of 85.81 was calculated. Three
studies [46, 47, 56] were assessed to have a fair
quality, while all others achieved a high quality
score. The objective of all studies was
represented in a clear manner (QHES item 1),
but seven did not state the perspective of the
study (QHES item 2) [22, 33, 37, 40, 45, 53, 56].
In three studies, data were not extracted from
the best available source (QHES item 3)
[32, 48, 49]. Six studies used data from a
subgroup analysis (QHES item 4)
[32, 36, 37, 42, 52, 53]. The majority of
studies, with the exception of one, handled
uncertainties properly (QHES item 5) [56]. All
studies, with the exception of five, performed
an incremental analysis for costs and outcomes
between the alternatives (QHES item 6)
[38, 39, 47, 51, 56]. Detailed information for
the methodology of data extraction was not
reported in four studies (QHES item 7)
[37, 46, 47, 56]. The majority of studies
fulfilled the criteria of QHES items 8 and 9.
Only four studies did not choose the
appropriate time horizon or did not discount
benefits and costs beyond 1 year (QHES item 8)
[43, 46, 51, 55]. Furthermore, four studies failed
to measure the costs appropriately or to describe
methods for estimations of quantities and unit
costs clearly (QHES item 9) [41, 46, 47, 56]. All
studies clearly stated the primary outcome
(QHES item 10). All studies, except for three,
stated valid health outcomes or gave a
justification for the measurement used if other
more valid and reliable measures were not
available (QHES item 11) [12, 47, 48]. In most
of the studies, the economic model, methods,
and analyses were displayed transparently,
except in four (QHES item 12) [22, 39, 46, 52].
All studies gave a justification for the choice of
limitations or assumptions (QHES item 13). The
authors of seven studies discussed explicitly the
direction and the magnitude of the potential
Table 3 Classiﬁcation of study quality
Points Study quality
0–24 Extremely poor
25–49 Poor
50–74 Fair
75–100 High
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bias (QHES item 14) [39–41, 43, 45, 52, 54]. All
studies provided proper conclusions or
recommendations based on results (QHES item
15). Finally, only six studies did not disclose the
source of funding (QHES item 16)
[22, 39, 42, 43, 46, 56].
Table 4 Results of the QHES assessment
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Score
van den Akker-van Marle et al. [32] x x – x x x x x x x x x x – x x 86
Behl et al. [33] x – x – x x x x x x x x x – x x 89
Blank et al. [34] x x x – x x x x x x x x x – x x 93
Blank et al. [35] x x x – x x x x x x x x x – x x 93
Carlson et al. [36] x x x x x x x x x x x x x – x x 94
Dong et al. [37] x – x x x x – x x x x x x – x x 85
Donnan et al. [38] x x x – x – x x x x x x x – x x 87
Dubinsky et al. [39] x x x – x – x x x x x – x x x – 82
Elkin et al. [40] x – x – x x x x x x x x x x x x 95
Hagaman et al. [22] x – x – x x x x x x x – x – x – 78
Hall et al. [41] x x x – x x x x – x x x x x x x 91
Hughes et al. [42] x x x x x x x x x x x x x – x – 91
Kapoor et al. [43] x x x – x x x – x x x x x x x – 89
Kauf et al. [44] x x x – x x x x x x x x x – x x 93
De Lima Lopes et al. [45] x – x – x x x x x x x x x x x x 95
Lyman et al. [46] x x x – x x – – – x x – x – x – 62
Marra et al. [47] x x x – x – – x – x – x x – x x 67
Nieves Calatrava et al. [48] x x – – x x x x x x – x x – x x 78
Oh et al. [49] x x – – x x x x x x x x x – x x 85
Plumpton et al. [50] x x x – x x x x x x x x x – x x 93
Priest et al. [51] x x x – x – x – x x x x x – x x 80
Rattanavipapong et al. [52] x x x x x x x x x x x – x x x x 92
Schackman et al. [53] x – x x x x x x x x x x x – x x 90
Shiroiwa et al. [54] x x x – x x x x x x x x x x x x 99
Thompson et al. [12] x x x – x x x x x x – x x – x x 86
Vijayaraghavan et al. [55] x x x – x x x – x x x x x – x x 86
Winter et al. [56] x – x – – – – x – x x x x – x – 58
Statement frequency 27 20 24 6 26 22 23 23 23 27 24 23 27 7 27 21
Response to QHES assessment question: present (x) or absent (–)
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Main Characteristics of the Studies
All main characteristics of the studies are
presented in Table 5. The included studies
were published between 2002 and 2015. In the
years 2000, 2001, and 2003 we did not find
publications that satisfied the inclusion criteria.
Two-thirds of the selected articles were
published in the last 7 years. Furthermore,
studies carried out in recent years (between
2009 and 2015) achieved a higher QHES average
score than those published previously. AZA is
the most frequently considered active
ingredient for which PT were evaluated (seven
Table 5 Number of studies in the main categories
Categories Number
of
studies
Mean QHES
score (range)
Number of included studies 27 85.81 (58–99)
Year of publication
2002–2008 10 79.6 (58–95)
2009–2015 17 89.47 (78–99)
Therapeutic areas
Epilepsy/neuropathic pain 3 90.00 (85–93)
HIV/AIDS 5 88.20 (78–93)
Immunology 7 76.57 (58–85)
Inﬂammatory bowel
disease
3 73.33 (58–82)
Rheumatologic conditions
(rheumatoid arthritis and
systematic upus
erythematosus)
2 76.00 (67–85)
IPF 1 78.00 (78)
Autoimmune disease 1 86.00 (86)
Oncology 12 89.17 (62–99)
Breast cancer (early stage) 3 82.00 (62–93)
Metastatic breast cancer 1 95.00 (95)
Metastatic colorectal
cancer
4 91.75 (86–99)
Acute lymphoblastic
leukemia
2 86.50 (86–87)
Advanced NSCLC 2 94.50 (94–95)
Active ingredient
Abacavir 5 88.20 (78–91)
Azathioprine 7 76.57 (58–86)
Carbamazepine 3 90.00 (85–93)
Cetuximab 3 93.67 (89–99)
Cetuximab ? panitumumab 1 86.00 (86)
Erlotinib 1 94.00 (94)
Geﬁtinib 1 95.00 (95)
Mercaptopurine 2 86.50 (86–87)
Table 5 continued
Categories Number
of
studies
Mean QHES
score (range)
Tamoxifen 2 76.50 (62–91)
Trastuzumab 2 94.00 (91–95)
Biomarker
EGFR 2 94.50 (94–95)
HER2 2 94.00 (93–95)
HLA-B*1502 2 88.50 (85–92)
HLA-B*5701 5 88.20 (78–93)
HOXB13-IL17BR 2 76.50 (62–91)
KRAS 4 91.75 (86–99)
HLA-A*31:01 1 93.00 (93)
TMPT 9 78.77 (58–87)
AIDS/HIV acquired immune deﬁciency syndrome/human
immunodeﬁciency virus, IPF idiopathic pulmonary
ﬁbrosis, NSCLC non-small cell lung cancer, EGFR
epidermal growth factor receptor, HER2 human
epidermal growth factor receptor 2, HLA-B*1502 human
leukocyte antigen B*1502, HLA-B*5701 human leukocyte
antigen B*5701, HOXB13-IL17BR two gene ratio, KRAS
Kirsten rat sarcoma viral oncogene homolog,
HLA-A*31:01 human leukocyte antigen 31:01, TMPT
thiopurine methyltransferase
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studies out of the 27 included here). Five of
these seven evaluations were published between
2002 and 2006, and the latest article was
published in 2014. TMPT, which predicts the
potential effectiveness of AZA application, is the
most commonly evaluated biomarker. Six of the
nine studies focusing on TMPT were published
between 2002 and 2006. Over two-fifth of the
studies included here evaluated the CE of
PT-guided therapy in oncological diseases.
Table 5 shows the subdivision of the included
studies according to the main categories as well
as QHES average score and range in the
corresponding category.
Cost-effectiveness of Pharmacogenetics
Testing in Specific Therapeutic Areas
Epilepsy
The cost-effectiveness of pharmacogenetics
testing in the treatment of epilepsy was
evaluated in three studies. The latest study
from Plumpton et al. [50] focused on the
HLA*A*31:01 allele screening test. An ICER of
£37,314 (US$53,674) per cutaneous avoided
ADR for a prior HLA*A*31:01 allele test and
carbamazepine (CBZ) administration following
the test result was calculated. Studies from Dong
et al. [37] and Rattanavipapong et al. [52] also
examined the CE of PT prior to CBZ
administration; however, these analyses aimed
at identifying the presence of the HLA-B*15:02
allele. Rattanavipapong et al. [52] examined the
influence of prescribing CBZ with and without
prior HLA-B*15:02 allele test for epilepsy as well
neuropathic pain. In the case of epilepsy, they
calculated an ICER of THB 220,000 (US$7066)
per QALY, while for neuropathic pain, the ICER
was THB 130,000 (US$4137) per QALY, gained
through PT and CBZ administration following
the test results. Dong et al. [37] investigated the
CE of HLA-B*15:02 allele testing prior to
initiation of CBZ therapy in Singapore. In
comparison with no testing and CBZ
prescription to all patients, the test
result-based CBZ administration achieved an
ICER of US$29,750. The frequency of
HLA-B*15:02 allele differs between the three
major ethnical populations present in
Singapore. Therefore, separate ICERs were
calculated for each of these groups. The test
strategy led to an ICER of US$37,030 per QALY
for Singapore Chinese, an ICER of US$7930 per
QALY for Singapore Malays, and an ICER of
US$136,630 per QALY for Singapore Indians.
Regarding the US$50,000 threshold, PT before
CBZ administration is cost-effective for
Singapore Malays and Singapore Chinese.
HIV/Aids
All HIV/AIDS studies included here analyzed
the CE of HLA-B*57:01 allele test before
abacavir (ABC) administration. Hughes et al.
[42] compared the CE of HLA-B*57:01 allele test
prior to ABC prescription (patients with a
positive test result received an alternative
treatment and patients without HLA-B*57:01
allele were treated with ABC) with that of
patients treated with ABC but not tested. A
dominant ICER was determined in the first
group. However, the incremental CE depends
on the costs of the alternative treatment: based
on the costs of the highly active antiretroviral
therapy (HAART) alternative, a range of
dominant ICER (alternative treatment is less
expensive and more effective) up to an €22,811
(US$26,714) per avoided HSR was calculated.
Schackman et al. [53] determined an ICER of
US$36,700 per QALY for a previous
HLA-B*57:01 allele test and a test result-based
treatment in comparison with no testing.
On the other hand, Nieves Calatrava et al.
[48] assessed an ICER of €630.16 (US$807) per
avoided HSR, and Kauf et al. [44] calculated an
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even lower ICER of only US$328 per avoided
HSR for a HLA-B*57:01 allele test-based ABC
treatment (as opposed to the prescription of
ABC without a predictive test).
The latest published study by Kapoor et al.
[43] provides a detailed analysis for HLA-B*57:01
allele testing before ABC prescription in three
ethnicities. Furthermore, differential results
regarding the disease stage (early and late stage)
and the treatment strategy (tenofovir and ABC
can be prescribed as first-line treatment while
some patients were contraindicated to tenofovir)
were described. For early stage treatment, where
tenofovir and ABC can be prescribed as first-line,
the CE for a HLA-B*57:01 allele test-based ABC
treatment (in contrast to administration of ABC
without testing) resulted in an ICER of
US$415,845 per QALY for Han-Chinese, an
ICER of US$318,029 per QALY for
Southeast-Asian Malays, and ICER of
US$208,231 per QALY for South-Asian Indians.
For this treatment line, where both active
ingredients were prescribed, a CE analysis was
also performed for patients at a later stage of the
disease. In the latter case, ICERs of US$926,938
per QALY for Han-Chinese, of US$624,297 per
QALY for Southeast-Asian Malays, and of
US$284,598 per QALY for South-Asian Indians
were calculated. This study also included a CE
analysis for these three patients groups
contraindicated for tenofovir. For the early
stage treatment group, ICERs of US$252,350
per QALY for Han-Chinese, of US$154,490 per
QALY for Southeast-Asian Malays, and of
US$44,649 per QALY for South-Asian Indians
were analyzed. For patients at a later stage of the
disease, ICERs of US$757,270 per QALY for
Han-Chinese, of US$454,223 per QALY for
Southeast-Asian Malays, and of US$114,068 per
QALY for South-Asian Indians were found. This
study indicates that a predictive test prior to ABC
administration is not effective, independently
of the disease stage. Exceptions are
tenofovir-contraindicated early-stage patients.
Immunology
Inflammatory Bowel Diseases Winter et al.
[56] conducted a CE analysis for a PT, which
analyzed TMPT activity. The dosage of AZA is
based on TMPT activity. Hence, a standard AZA
dose without prior testing was compared to an
activity-based AZA dosage administration. Costs
of £487 (US$776) per LSY for a 30-year-old
patient and of £951 (US$1515) for a 60-year-old
patient were determined.
On the other hand, Dubinsky et al. [39] and
Priest et al. [51] identified CE for a genotype
test-based TMPT activity initiation of AZA,
compared to administering a standard dosage
of AZA without a prior predictive test.
Furthermore, Priest et al. [51] compared the
phenotypic and genotypic testing and showed
that the phenotypic TMPT test strategy was the
most cost-effective approach.
Rheumatologic Conditions (Rheumatoid
Arthritis and Systematic Lupus
Erythematosus) Marra et al. [47] and Oh
et al. [49] evaluated the CE of PT in the
therapeutic area of rheumatologic conditions.
In both studies, administering a TMPT test
result-based dose of AZA is more effective and
less costly than administering a standard dose
of AZA without prior testing.
Idiopathic Pulmonary Fibrosis Hagaman
et al. [22] evaluated the CE of TMPT testing in
idiopathic pulmonary fibrosis. The performance
of a TMPT test and the test result-based AZA
dosage (in contrast to the administration of a
standard dose AZA without prior TMPT test)
resulted in an ICER of US$29,663 per QALY.
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Autoimmune Disease Thompson et al. [12]
investigated the CE of TMPT testing prior to
AZA administration in autoimmune diseases.
An incremental cost of £421.06 (US$625) and
an incremental net benefit of £256.89 (US$381)
for TMPT activity test prior to AZA
administration (in contrast to the
administration of a standard dose of AZA
without TMPT test) were determined.
Oncology
Breast Cancer (Early Stage) Lyman et al. [46]
investigated the CE of PT in early stage breast
cancer relative to the recurrence of the disease.
A comparison between testing the risk of relapse
and administration of the standard therapy,
consisting of tamoxifen and chemotherapy, was
conducted. Patients at low risk of relapse only
received tamoxifen, the others tamoxifen and
chemotherapy. Lyman et al. [46] determined an
ICER of US$3385 per LYS (no indication of age),
whereas Hall et al. [41] indicate an ICER of
US$8852 per QALY (patients above 60 years of
age). In this study, Hall et al. [41] concluded
that a general statement on the
cost-effectiveness could not be made because
of substantial uncertainties.
Blank et al. [34] investigated the CE of PT in
early stage breast cancer prior to administration
of trastuzumab. In this study a comparison of a
test result-based administration of trastuzumab
and the administration of the drug without a
prior test was conducted. In the test strategy,
patients with proven HER2 overexpression
received trastuzumab, whereas patients
without HER2 overexpression received an
alternative therapy. Two testing procedures
were considered: immunohistochemistry (IHC
test) and fluorescence in situ hybridization
(FISH test). The therapy with both tests alone
or in combination (compared with no previous
test) had significantly lower costs, but the FISH
test alone was considered the most
cost-effective approach. However,
administering trastuzumab with no previous
test achieved a higher benefit, as a result of the
imperfect sensitivity and specificity of the tests.
A CE ratio was not calculated.
Metastatic Breast Cancer Elkin et al. [40]
evaluated the CE of PT prior to trastuzumab
administration in metastatic breast cancer.
HER2 overexpression test prior to trastuzumab
prescription was compared with the
prescription of trastuzumab and chemotherapy
without a predictive test. Patients with HER2
overexpression received a combination
treatment, consisting of trastuzumab and
chemotherapy. Patients without HER2
overexpression only received chemotherapy.
In this study, IHC and FISH tests were used to
determine HER2 overexpression. The use of a
FISH test resulted in a dominant ICER.
Furthermore, performing the IHC test before
the FISH test was the most cost-effective
approach. However, the benefit provided by
this strategy compared to trastuzumab
administration without prior test was less.
Metastatic Colorectal Cancer Shiroiwa et al.
[54] analyzed the CE of a PT prior
administration of cetuximab in metastatic
colorectal cancer. A comparison of KRAS
mutation test and a result-based
administration of cetuximab (patients with
wild-type KRAS received cetuximab and
patients with KRAS mutations received best
supportive care, BSC) and cetuximab
treatment without a predictive test were
conducted. A dominant ICER for the testing
strategy was determined.
Vijayaraghavan et al. [55] determined the
cost-effectiveness of a KRAS mutation test prior
to administration of cetuximab monotherapy,
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treatment with cetuximab in combination with
chemotherapeutics, and panitumumab
monotherapy. Patients with a KRAS mutation
received exclusively chemotherapeutics in
combination therapy and BSC for
monotherapy. The use of a KRAS mutation test
before prescription of cetuximab monotherapy,
panitumumab monotherapy, and cetuximab
combination therapy achieved a dominant
ICER compared to the treatment without the
predictive test.
Blank et al. [35] evaluated the CE for a KRAS
mutation test and a subsequent BRAF gene test
before administration of cetuximab in
combination with BSC for metastatic colorectal
cancer. Patients with a KRAS or BRAF mutation
received exclusively BSC. The subsequent
verification of BRAF status after KRAS test was
the most cost-effective approach compared to
treating all patients without testing or solely
after the KRAS test. However, perhaps as a result
of the imperfect sensitivity and specificity, there
was a higher benefit in prescribing cetuximab
without a prior test compared with the test
strategies. An ICER for a predictive test prior
cetuximab administration as compared to
without prior testing and treating all patients
with cetuximab was not reported.
Behl et al. [33] also evaluated the CE of a
subsequent BRAF gene test in addition to a
KRAS mutation analysis prior to cetuximab
administration in combination with BSC. The
subsequent verification of BRAS status after the
KRAS test was also the most cost-effective
approach. However, even in this case, perhaps
as a result of the imperfect sensitivity and
specificity of the testing procedures, cetuximab
without a prior test led to a higher benefit. An
ICER was not stated.
Acute Lymphoblastic Leukemia Van den
Akker-van Marle et al. [32] conducted a CE
study for a PT prior to mercaptopurine
administration in acute lymphoblastic
leukemia in children. There, an ICER of €4800
(US$5702) per LYG for a genotypic TMPT
activity test and TMPT activity-based
mercaptopurine dosage, compared to no
testing and administration of a standard initial
dose of mercaptopurine, was determined.
On the other hand, in the study by Donnan
et al. [38] neither a phenotypic nor a genotypic
test for determining TMPT activity prior to
mercaptopurine administration proved to be
cost-effective (higher costs for the same
benefit).
Advanced Non-Small Cell Lung
Cancer Carlson et al. [36] conducted a CE
study for a PT prior to erlotinib administration
in advanced non-small cell lung cancer
patients. A comparison was made between the
use of an EGFR test and the result-based
erlotinib administration in patients with EGFR
mutations or an alternative therapy for patients
without EGFR mutation, and the treatment of
all patients with erlotinib without a prior test.
An ICER of US$162,018 per QALY for the use of
a gene copy number test was determined. The
ICER clearly surpassed that of the study set
threshold of US$100,000 to US$150,000 per
QALY.
De Lima Lopes et al. [45] evaluated the
cost-effectiveness of the EGFR test prior to
gefitinib prescription. A dominant ICER for
the comparison of the use of an EGFR test
prior to gefitinib administration and no testing
while prescribing chemotherapy with
subsequent gefitinib administration was
determined. In the test strategy, patients with
an EGFR mutation received gefitinib followed
by chemotherapy as second-line therapy.
Patients without EGFR mutation received
chemotherapy with subsequent BSC.
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Main Results of This Systematic Review
In this systematic review, six main results were
obtained:
1. In the majority of studies, a PT-guided
administration of an active ingredient was
found to be cost-effective or leads to cost
savings.
2. A general statement on CE for a test-guided
application of an active ingredient
(independently of the indication for which
it has been prescribed) was not observed.
3. The majority of studies analyzed the CE of
targeted therapies in oncological diseases.
4. The CE depends on various factors (e.g.,
prevalence of biomarkers, test costs,
threshold value, prevalence of ADRs,
response rate of therapy).
5. The CE of a PT-guided therapy can differ
between indications as well as within the
same indication.
6. The results depend on the perspective of the
study (society, healthcare system, and
payer).
DISCUSSION
This comprehensive review analyzed the CE of
PT-guided therapies. For this propose we
included only studies that compared the CE of
the administration of an active ingredient with
or without a prior predictive test. PTs serve to
determine the effectiveness of active
ingredients, to take a therapeutic decision, and
ultimately to optimize patient benefit by
avoiding ADRs. Preventing ADRs leads to an
increase in drug safety and is therefore the
central argument for the application of PTs
[57, 58]. However, the usefulness of such
pharmacogenetic tools depends on their CE.
CE analyses are essential for reimbursement
decisions of new technologies as well as pricing
by decision-makers. This review investigated
whether PTs contribute to an efficient therapy
management.
An average value of 85.81 for all 27 assessed
studies was calculated. The evaluation through
the QHES instrument is a quality assessment
regarding the methodology of the studies. This
evaluation considered the specific stratified
medicine inadequate. Important criteria in the
assessment of PTs are the prevalence of
biomarkers, sensitivity, and specificity of the
test, as well testing costs.
Generally, innovations are used if they have
a significant influence on the outcomes (e.g., on
the survival or on the improvement in the
quality of life). As a result of the limited
healthcare budget, it is essential to assess the
additional benefits of the innovation in
comparison with previous standards.
Therefore, CE analyses are necessary and were
used for reimbursement decisions. The CE of a
medical intervention depends on whether it
will be able to provide benefits at a reasonable
cost. CE analyses estimate the ICER of
interventions. ICER is an analytical tool of the
CE analysis (CEA), which compares the
differences in cost of two treatments based on
their different outcomes (e.g., new treatment vs.
previous treatment). Threshold values vary
from country to country. For example, a
threshold of US$50,000 is stated as
cost-effective in the USA [59]. An intervention
with an ICER of less than US$50,000 per
additional QALY is classified as cost-effective.
The CE depends on several factors. In this
comprehensive review some divergent features
in the study design, which influenced the CE,
were identified.
Perspective of the study The CE of a study
depends, among other things, on the chosen
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perspective (e.g., healthcare system, society)
[60]. The missing consideration of indirect cost
allows no final assessment and comprehensive
interpretation. Ideally, the cost should be
collected from a societal perspective. However,
for this purpose, the required costs are difficult
to quantify (e.g., loss of wages) [61].
Time horizon/discounting Different CE values
arise because of the various time horizons. For
the consideration of ADRs, a time horizon of
1 year would be sufficient. This is because ADRs
caused by pharmacogenetic applications
immediately appear after the active ingredient
has been administered [62]. A defined time
horizon would lead to an improved
comparability. In contrast, for the
consideration of pharmacodynamic effects, a
life-long time horizon should be considered,
since the costs for long-term consequences or
the avoidance of them have a considerable
importance.
Impact of sensitivity and specificity of the test
procedures Weaknesses in the sensitivity and
specificity of the predictive tests may influence
the CE of a strategy. Sensitivity and specificity
are characterized by a great heterogeneity. This
could lead to an incorrect classification as
responder or non-responder. Thus, it may
result in the administration of ineffective
drugs, undesirable effects, or the exclusion of
an effective therapy. Generally, this implies
losses of effectiveness for the relevant therapy.
Prevalence of biomarkers Biomarker prevalence
in the specific study populations is based on
different assumptions. Dong et al. [37]
differentiated the study population according
to allele frequencies. The HLA-B*1502 allele
frequencies differ between various ethnic
groups. The corresponding classification leads
to an increased degree of stratification.
Fundamentally, a lower biomarker prevalence
leads to a lower CE of the PT [63]. According to
the lower likelihood to identify a responder, the
overall benefit is low. Homogenous groups
enable an increase in test validity or the
likelihood to identify a responder, as well as
the examination of biomarker prevalence values
by sensitivity analysis.
Costs of testing procedures Various yearly
prices, countries, test characteristics, lack of
transparency on test prices, as well as often used
estimates, reduce the possibility of comparing
the costs of testing procedures. Sensitivity
analyses of the price may reduce the
incomparableness. Possible future cost
reductions of PTs will have a positive impact
on the CE.
Lack of evidence-based data The data used for
CE evaluations are partially of insufficient
quality and quantity. The evaluations often
derived from retrospective studies. Randomized
controlled trials (RCT) enable the generation of
evidence-based data and provide a valid basis for
CEA. RCTs are regarded as the gold standard of
data collection [64, 65]. The main problems in
this context are low funding, low interest in
clinical trials (except studies for approved
medications), small patient populations, as well
as lack of valid discoveries [66]. It is difficult to
conduct an RCT for pharmacogenetic
applications. The anticipated differences in
treatment effectiveness accompanying the test
strategies and the need to generate significant
outcomes in patients with a similar genotype
require large group sizes [67].
Oncology is the most frequently discussed
disease area for CEA. This indication area is
characterized by the high toxicity of
chemotherapeutic agents as well as poor
clinical outcomes [68, 69]. This raises the
potential to be one of the largest and most
attractive fields for pharmacogenomics
application. Oncology is particular well suited
to show CE, because it is an area with a large
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number of affected patients and with expensive
cancer-associated outcomes (chronic pain,
ADRs, death). Minor improvements of
outcomes affect the CE, because expensive
outcomes such as long hospital stays can be
prevented.
There are some economic, clinical, and
practical challenges in connection with the
development and the application of PTs.
Research and development of
pharmacogenetic applications is characterized
by some regulatory challenges [70, 71] and high
costs to prove clinical benefits [72]. There is a
disincentive for pharmaceutical companies to
invest in companion diagnostics [73, 74]: an
investment into a market without free pricing is
a risk for pharmaceutical companies. Genetic
analyses (subgroup analysis) divide the market
and reduce the total turnover. In countries
without the possibility of dynamic pricing or
changes in price according to subgroups or
indications, the different value of PTs for the
specific subgroups is appropriate. A general
problem of personalized medicine is the
development of drugs for small patient groups
but with the same costs of the research and
development needed for the development of
drugs for larger groups [75]. The danger of low
total turnover by small user groups hinders
further research and development in the field of
targeted therapies. Therefore, in areas with
larger market segmentations, pharmacogenetic
research should be financed by public resources
[76]. Moreover, payers link pharmacogenetic
applications with concerns. PTs as well as
proteomic tests seem to be more expensive
than conventional diagnostic and prognostic
tools [77]. Actually, only a few pharmacogenetic
examinations were financed within the uniform
value scale, on the basis of pricing of ambulant
services (EBM). Performing a PT for eight of 47
active ingredients is not compulsory. For 10 of
these 47 active ingredients CEA were
conducted. The insufficient basis for a
conclusion can be used as a reason for the
restrained reimbursement for PTs.
Furthermore, the clinical benefit of an
intervention (e.g., CE, net benefit) is an
essential prerequisite for PT application.
However, because of the lack of evidence for
the correlation between the influence of a PT on
the clinical outcome [78], it is difficult to prove
the benefit. No test can perfectly predict
whether a patient will respond positively to a
particular treatment. Various factors influence
the therapeutic outcome. Generally, ADRs often
occur immediately after treatment [79]. Thus,
the outcomes (e.g., cost per avoided ADR) can
be quickly and easily observed [61], especially in
oncological studies. Moreover, the effects also
depend on monitoring ADR quality.
Some practical challenges are connected
with the routine use of PT. The partly missing
reimbursement [27, 80], the lack of clinical
guidelines [81], and the processing time
associated with treatment delays [82] preclude
their widespread application. Furthermore, the
use of PT essentially depends on its acceptance
by physicians [83]. The restrained use of PT is
the result of the missing clinical validation for
the clinical application as well of the missing
practical and standardized guidelines [84].
There are also ethical concerns regarding the
use of PT. Patients were excluded from target
therapies as a result of the test results. The
insufficient sensitivity and specificity of PTs
may lead to a wrong stratification and therefore
to the lack of an effective treatment.
The costs of the tests and which savings
could be achieved through the use of predictive
tests must be known. If there are higher savings,
it is economically sensible to conduct a PT. In
modelling the CE of PT, important factors such
as the sensitivity and specificity of these tests,
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degree of gene penetrance, association between
genotype and clinical outcome, genotype
prevalence in the population, likelihood for
ADR, and survival according to the genotype
and the treatment strategy should be
considered.
The quality assessment through the QHES
may be subjective and may represent a major
limitation of this study. The assessment of study
aspects is easy to determine. In contrast, aspects
which aim to evaluate the adequacy are
characterized by variances. Therefore, two
researchers performed the assessment
independently to minimize this subjectivity of
the QHES instrument.
National and international standards for the
assessment of PT should be defined and
implemented to improve the quality of the
study. Uncertainties may be decreased by more
accurate estimations of effectiveness and costs
[85]. Furthermore, an independent financing
system (e.g., public financing) could enhance
the credibility of the results. Such studies are
focusing not solely on effectiveness but also on
efficiency.
CONCLUSION
The application of personalized therapies is
partly associated with high economic costs.
This review has demonstrated that, in the
majority of the studies included here,
test-guided personalized therapies are more
cost-effective than non-test-guided personalized
therapies. Hence, a prior test before drug
administration seems to be useful for
therapeutic decisions, dosing according to the
different genotypes or gene activity, and/or
reducing adverse drug reactions. However, the
results of the studies are mainly influenced, e.g.,
by sensitivity and specificity of the test
procedures, prevalence of biomarkers, and the
perspective of the study. Generally, analyses of
the CE are an essential part of the
reimbursement recommendations. However, to
guarantee a comparability of CE of stratified drug
therapies, national and international standards
for evaluations studies should be defined.
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